Publication | Open Access

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

AsthmaPulmonary CarePhase 2BPharmacologyUnexplained Chronic CoughPulmonary PharmacologyPharmacotherapyMedicineP2x3 Receptor Antagonist